P513: Prospective study on patients' satisfaction and impact on quality of life of corticosteroid therapy in patients with Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Navarro Llavat, M.(1)*;García-Bosch, O.(1);Castro-Poceiro, J.(1);Bargalló García, A.(1);Ruiz Arroyo , D.(1);Navas Bravo , Y.(1);Erice Muñoz, E.(1);Barquero Declara, D.(1);Mata Bilbao, A.(1);Martín Llahí , M.(1);Ariza Solé, X.(1);Hernández Ballesteros, C.(1);Juan Juan , A.(1);Bustamante Robles, K.(1);Berbel Comas, C.(1);Blasco Pelicano, A.(1);Albareda Riera, M.(2);Domènech Morral , E.(3);
(1)Hospital Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain;(2)Hospital Moisès Broggi, Endocrinology and Nutrition, Sant Joan Despí, Spain;(3)Hospital Germans Trias i Pujol and Centro de Investigaciones en Red en Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Badalona, Spain;
P514: Serum levels of Klotho in inflammatory bowel disease: an exploratory studyECCO’23 CopenhagenYear: 2023
Authors: Hernandez-Camba, A.(1,2);Rodriguez-Jimenez, J.(1)*;Carrillo Palau, M.(3);Ramos Lopez, L.(3);Perez-Mendez , L.(4,5);Martin-Nuñez , E.(6);Alonso, I.(3);Vela, M.(1);Hernandez Alverez Builla, N.(3);Arranz, L.(1);Hernandez, A.(3);Ferraz Amaro, I.(7);Navarro‐Gonzalez, J.F.(6,8,9);
(1)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(2)Nursing School Nuestra Señora de Candelaria- La Laguna University, Anatomy and Histology, Santa Cruz de Tenerife, Spain;(3)Hospital Universitario de Canarias, Gastroenterology, La Laguna, Spain;(4)Hospital Universitario de Nuestra Señora de Candelaria y Gerencia de Atención Primaria, Clinical Epidemiology and Bioestadistics Division- Research Unit, Santa Cruz de Tenerife, Spain;(5)Center for Biomedical Research in Respiratory Diseases Network CIBER, Instituto de Salud Carlos III, Madrid, Spain;(6)Hospital Universitario Nuestra Señora de Candelaria, Research Unit, Santa Cruz de Tenerife, Spain;(7)Hospital Universitario de Canarias, Rheumatology, La Laguna, Spain;(8)La Laguna University, Institute of Biomedical Technologies, La Laguna, Spain;(9)Hospital Universitario Nuestra Señora de Candelaria, Nephrology, Santa Cruz de Tenerife, Spain;
P515: Infliximab desensitization in patients with Inflammatory Bowel Diseases: a safe therapeutic alternativeECCO’23 CopenhagenYear: 2023
Authors: Hammoudi, N.(1)*;Hassid, D.(1);Bonnet, J.(1);Tran Minh, M.L.(1);Baudry, C.(1);Chedouba, L.(1);Vauthier, A.(1);Gornet, J.M.(1);Allez, M.(1);
(1)APHP Saint Louis, Gastroenterology, Paris, France;
P516: Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension studyECCO’23 CopenhagenYear: 2023
Authors: Caldera, F.(1)*;Maddux, R.(2);Ungaro, R.(3);Kaur, A.(2);Brown, E.(2);Hu, S.(2);Sheffield, J.K.(2);Silva, D.(2);Harris, S.(2);Cree, B.A.C.(4);
(1)University of Wisconsin School of Medicine and Public Health, Gastroenterology and Hepatology, Madison, United States;(2)Bristol Myers Squibb, Clinical Research, Princeton, United States;(3)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;(4)University of California San Francisco, Weill Institute for Neurosciences- Department of Neurology, San Francisco, United States;
P517: Ustekinumab monitoring levels predict the need for intensification in patients with inflammatory bowel disease.ECCO’23 CopenhagenYear: 2023
Authors: Ramos Lopez, L.(1);Ramos-Díaz, R.(2);Alonso-Abreu, I.(1);Mourani-Padron, I.(2);Carrillo-Palau, M.(1);Reygosa, M.C.(1)*;Medina-Chico, S.(1);Gutierrez-Nicolas, F.(3);Nazco-Casariego, G.J.(3);Hernandez-Guerra, M.(4);
(1)Hospital Universitario De Canarias, IBD Unit. Gastroenterology Department, La Laguna, Spain;(2)Hospital Universitario de Canarias, Fundación Canaria Instituto de Investigación Sanitaria de Canarias FIISC, La Laguna, Spain;(3)Hospital Universitario de Canarias, Hospital Pharmacy Department, La Laguna, Spain;(4)Hospital Universitario de Canarias, Gastroenterology Department, La Laguna, Spain;
P518: Safety of upadacitinib in ulcerative colitis: Long-term data from the phase 3 open-label extension study (U-ACTIVATE)ECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Lichtenstein, G.(2);Nakase, H.(3);Armuzzi, A.(4);Kucharzik, T.(5);Levy, G.(6);Palac, H.(6);Kujawski, M.(6);Klaff, J.(6);Cheon, J.H.(7);
(1)University of Calgary Department of Medicine, Division of Gastroenterology and Hepatology, Calgary, Canada;(2)University of Pennsylvania School of Medicine, Division of Gastroenterology, Philadelphia, United States;(3)Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan;(4)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;(5)Klinikum Lüneburg, Division of Gastroenterology and Hepatology, Lüneburg, Germany;(6)AbbVie Inc, Immunology, North Chicago, United States;(7)Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, Korea- Republic Of;
P520: Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programmeECCO’23 CopenhagenYear: 2023
Authors: van der Woude, J.(1)*;Schreiber , S.(2);Peyrin-Biroulet , L.(3);Szekanecz, Z.(4);Choy, E.H.(5);Stiers, P.J.(6);Van Hoek, P.(7);Van Beneden, K.(8);de Haas, A.(9);Rudolph , C.(10);ten Cate, H.(11);
(1)Erasmus Medical Center Hospital, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(2)University Hospital Schleswig-Holstein, Department Medicine I, Kiel, Germany;(3)University Hospital of Nancy, Division of Gastroenterology, Vandoeuvre-lès-Nancy, France;(4)University of Debrecen, Department of Rheumatology- Faculty of Medicine, Debrecen, Hungary;(5)Cardiff University School of Medicine, CREATE Centre- Section of Rheumatology- Division of Infection and Immunity, Cardiff, United Kingdom;(6)Galapagos NV, Biostatistics Department, Mechelen, Belgium;(7)Galapagos NV, Clinical Development Department, Mechelen, Belgium;(8)Galapagos NV, Medical Affairs Department, Mechelen, Belgium;(9)Galapagos NV, Clinical Development Department, Leiden, The Netherlands;(10)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(11)Maastricht University Medical Centre, Department of Internal Medicine, Maastricht, The Netherlands;
P521: Effectiveness of ustekinumab as therapy for chronic antibiotic refractory pouchitisECCO’23 CopenhagenYear: 2023
Authors: Outtier, A.(1)*;Louis, E.(2);Dewit, O.(3);Schops, G.(1);Verstockt, B.(1);Sabino, J.(1);Vermeire, S.(1);Ferrante, M.(1);
(1)UZ Leuven, Gastroenterology, Leuven, Belgium;(2)CHU Liège, Gastroenterology, Liège, Belgium;(3)Cliniques Universitaires Saint-Luc, Gastroenterology, Bruxelles, Belgium;
P522: Kono-S anastomosis reduces endoscopic and surgical post-operative recurrence in Crohn's disease. The SuPREMe-CD Trial Update.ECCO’23 CopenhagenYear: 2023
Authors: Luglio, G.(1)*;Rispo, A.(2);Tropeano, F.P.(3);Giglio, M.C.(4);Cricrì, M.(4);Imperatore, N.(5);De Sire, R.(4);Guarino, A.D.(4);Bucci, L.(6);Castiglione, F.(4);De Palma, G.D.(4);
(1)University of Naples Federico II, Department of Public Health - Surgical Endoscopy Unit, Napoli, Italy;(2)University of Naples Federico II, Department of Clinical Medicine and Surgery - Gastroenterology Unit, Naples, Italy;(3)University of Naples Federico II, Department of Advanced Biomedical Sciences, Naples, Italy;(4)University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy;(5)Ospedale Santa Maria delle Grazie Pozzuoli, Department of Medicine, Pozzuoli, Italy;(6)University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy;
P523: Quality, safety and equity of care outcomes for inflammatory bowel disease patients at four tertiary referral centres in Australia using a cloud based management system Crohn's Colitis Care (CCCare): A real world observational study.ECCO’23 CopenhagenYear: 2023
Authors: Cheema, M.(1)*;Narouz, I.(2);Pipicella, J.(3);Garden , F.(4);Lynch, K.(5);Andrews, J.(5);Ghaly, S.(2);Connor, S.(1);
(1)Liverpool Hospital, Department of Gastroenterology and Hepatology, Liverpool, Australia;(2)St. Vincent's hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(3)University of New South Wales, Medicine SWS Clinical School, Liverpool, Australia;(4)University of New South Wales, School of Clinical Medicine- South Western Sydney Clinical Campus, Liverpool, Australia;(5)Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia;
P524: Predictors of immunogenicity in patients with Inflammatory Bowel Disease treated with infliximab: A post hoc analysis of the randomised phase I CT-P13 SC studyECCO’23 CopenhagenYear: 2023
Authors: Schreiber, S.(1);Ben-Horin, S.(2);Ye, B.D.(3);Kim, D.H.(4);Reinisch, W.(5)*;
(1)University Hospital Schleswig-Holstein, Department for Internal Medicine I, Kiel, Germany;(2)Tel Aviv University, Gastroenterology Department- Chaim Sheba Medical Center, Tel-Hashomer, Israel;(3)University of Ulsan College of Medicine, Department of Gastroenterology and Inflammatory Bowel Disease Center- Asan Medical Center, Seoul, Korea- Republic Of;(4)Celltrion Healthcare Co., Ltd, Incheon, Korea- Republic Of;(5)Medical University of Vienna, Department of Internal Medicine III- Division of Gastroenterology and Hepatology, Vienna, Austria;
P525: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis: a systematic review and meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Taxonera, C.(1)*;Olivares, D.(1);Olga N, L.G.(2);Alba, C.(1);
(1)Hospital Clínico San Carlos, IBD Unit- Department of Gastroenterology, Madrid, Spain;(2)Hospital Clínico San Carlos, Department of Gastroenterology, Madrid, Spain;
P526: A prediction model for successful increase of adalimumab dose intervals: analysis of the pragmatic open-label randomised controlled non-inferiority LADI trialECCO’23 CopenhagenYear: 2023
Authors: Van Linschoten, R.(1,2)*;Jansen, F.(3);Pauwels, R.(2);Smits, L.(3);Atsma, F.(4);Kievit, W.(5);de Jong, D.(3);de Vries, A.(2);Boekema, P.(6);West, R.(1);Bodelier, A.(7);Gisbertz, I.(8);Wolfhagen, F.(9);Romkens, T.(10);Lutgens, M.(11);van Bodegraven, A.(12);Oldenburg, B.(13);Pierik, M.(14);Russel, M.(15);de Boer, N.(16);Mallant-Hent, R.(17);ter Borg, P.(18);van der Meulen-de Jong, A.(19);Jansen, J.(20);Jansen, S.(21);Tan, A.(22);van der Woude, C.J.(2);Hoentjen, F.(23);
(1)Franciscus Gasthuis & Vlietland, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(2)Erasmus MC, Department of Gastroenterology & Hepatology, Rotterdam, The Netherlands;(3)Radboud University Medical Center, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(4)Radboud University Medical Center, IQ Healthcare, Nijmegen, The Netherlands;(5)Radboud University Medical Center, Radboud institute for Health Science- Department for Health Evidence, Nijmegen, The Netherlands;(6)Maxima Medical Center, Department of Gastroenterology and Hepatology, Eindhoven, The Netherlands;(7)Amphia Hospital, Department of Gastroenterology and Hepatology, Breda, The Netherlands;(8)Bernhoven Hospital, Department of Gastroenterology and Hepatology, Uden, The Netherlands;(9)Albert Schweitzer Hospital, Department of Gastroenterology and Hepatology, Dordrecht, The Netherlands;(10)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 's-Hertogenbosch, The Netherlands;(11)Elisabeth Tweesteden Hospital, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;(12)Zuyderland Medical Center, Dept. of Gastroenterology- Geriatrics- Internal and Intensive Care Medicine Co-MIK, Sittard-Geleen/Heerlen, The Netherlands;(13)University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(14)Maastricht University Medical Center+, Department of Gastroenterology and Hepatology, Maasstricht, The Netherlands;(15)Medisch Spectrum Twente, Department of Gastroenterology and Hepatology, Twente, The Netherlands;(16)Amsterdam University Medical Center- Vrije University Amsterdam, Department of Gastroenterology and Hepatology- AGEM research institute, Amsterdam, The Netherlands;(17)Flevoziekenhuis, Department of Gastroenterology and Hepatology, Almere, The Netherlands;(18)Ikazia Hospital, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(19)Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;(20)OLVG, Department of Gastroenterology and Hepatology, Roterdam, The Netherlands;(21)Reinier de Graaf Gasthuis, Department of Gastroenterology and Hepatology, Delft, The Netherlands;(22)Canisius Wilhelmina Hospital, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands;(23)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;on behalf of the LADI study group and the Dutch Initiative on Crohn and Colitis (ICC)
P527: Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Tanaka, A.(1)*;Kanmura, S.(1);Maeda, N.(1);Kuwazuru, K.(1);Komaki, F.(1);Komaki, Y.(1);Ido, A.(1);
(1)Kagoshima University Graduate School of Medical and Dental Sciences, Digestive and Lifestyle Diseases, Kagoshima city, Japan;
P528: Effectiveness, Safety and Incremental Costs of Proactive Therapeutic Drug Monitoring of Infliximab in a Prospective Cohort of Inflammatory Bowel Disease PatientsECCO’23 CopenhagenYear: 2023
Authors: Zelinkova, Z.(1)*;Podmanicky, D.(2);Kadleckova, B.(1);
(1)Nemocnica Bory - Penta Hospitals, Department of Gastroenterology, Bratislava, Slovakia;(2)Nemocnica Bory - Penta Hospitals, Department of Surgery, Bratislava, Slovakia;
P529: Year-two follow-up results of an observational study conducted in Crohn's disease and ulcerative colitis patients treated with infliximab biosimilar CT-P13 in a real-life settingECCO’23 CopenhagenYear: 2023
Authors: Laharie, D.(1)*;Pierron, G.(2);Brault, Y.(3);Bouhnik, Y.(4);Nancey, S.(5);
(1)University Hospital Center of Bordeaux, Department of Gastroenterology, Bordeaux, France;(2)Pfizer, Inflammation and Immunology, Paris, France;(3)Pfizer, Statistics, Paris, France;(4)Groupe hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France;(5)Lyon South Hospital- Pierre-Bénite- and INSERM U1111-CIRI, Department of Gastroenterology, Lyon, France;
P531: A model-based tool for guiding infliximab induction dosing to maximise long-term deep remission in children with inflammatory bowel diseasesECCO’23 CopenhagenYear: 2023
Authors: Kantasiripitak, W.(1);WIcha, S.G.(2);Thomas, D.(1);Hoffman , I.(3);Ferrante , M.(4,5);Vermeire , S.(4,5);van Hoeve , K.(3);Dreesen, E.(1,6)*;
(1)University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University of Hamburg, Department of Clinical Pharmacy, Hamburg, Germany;(3)University Hospitals Leuven, Department of Paediatric Gastroenterology- Hepatology- and Nutrition, Leuven, Belgium;(4)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)University of Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(6)University of California, Department of Bioengineering and Therapeutic Sciences, Leuven, Belgium;
P532: 1-Year Clinical Outcome of Subcutaneous Infliximab compared with Intravenous Infliximab in Patients with Inflammatory Bowel Disease During Maintenance TherapyECCO’23 CopenhagenYear: 2023
Authors: Song, J.H.(1);Hong, S.N.(2)*;Kim, E.R.(3);Kim, J.E.(3);Chang, D.K.(3);Kim, Y.H.(3);
(1)Samsung Medical Center- Sungkyunkwan University School of Medicine, Medicine- - Seoul- Korea, Seoul, Korea- Republic Of;(2)Samsung Medical Center- Sungkyunkwan University School of Medicine, Department of Medicine, Seoul, Korea- Republic Of;(3)Samsung Medical Center- Sungkyunkwan University School of Medicine, Medicine, Seoul, Korea- Republic Of;
